Search Results for 'Dolutegravir-Dtg'

Dolutegravir-Dtg published presentations and documents on DocSlides.

Dolutegravir-Lamivudine (

Dolutegravir-Lamivudine (

by audrey

Dovato. ). Last Updated: November 28, 2022. Prepar...

New regimen for $75 a year

New regimen for $75 a year

by tawny-fly

New pricing agreement will speed up access to gen...

DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT

DURABLE EFFICACY OF DOLUTEGRAVIR (DTG) PLUS LAMIVUDINE (3TC) IN ANTIRETROVIRAL TREATMENT

by jasmine

–. NAIVE ADULTS WITH HIV-1 INFECTION: 96-WEEK RE...

Superior Efficacy of Dolutegravir (DTG) Plus

Superior Efficacy of Dolutegravir (DTG) Plus

by celsa-spraggs

2 Nucleoside Reverse Transcriptase Inhibitors (NR...

Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV

Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV

by kylo

Andrew Hill, Francois Venter, Eric . Delaporte. , ...

DTG + TAF/FTC vs DTG + TDF/FTC vs EFV/TDF/FTC

DTG + TAF/FTC vs DTG + TDF/FTC vs EFV/TDF/FTC

by iris

ADVANCE. . Design. Primary endpoint. Proportion ...

DTG + 3TC versus DTG + TDF-FTC as Initial ART

DTG + 3TC versus DTG + TDF-FTC as Initial ART

by della

GEMINI 1 and GEMINI 2: Week 48 Data. DTG + 3TC . v...

Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials

Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV: ADVANCE and NAMSAL trials

by luanne-stotts

Progressive rises in weight and clinical obesity ...

Dolutegravir ( Tivicay )

Dolutegravir ( Tivicay )

by brown

Prepared by:. Brian R. Wood, MD. David H. Spach, M...

Dolutegravir vs. Raltegravir

Dolutegravir vs. Raltegravir

by zoe

SPRING-2 Study. Dolutegravir. versus Raltegravir....

Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

Dolutegravir + 2 NRTIs versus Darunavir + RTV + 2 NRTIs

by roxanne

FLAMINGO. Dolutegravir + 2 NRTIs versus Darunavir ...

Dolutegravir plus Rilpivirine as Maintenance Dual Therapy

Dolutegravir plus Rilpivirine as Maintenance Dual Therapy

by quinn

SWORD-1 . and SWORD-. 2. Dolutegravir plus Rilpivi...

Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents

Effect of dolutegravir on folate and vitamin B12 status among HIV-infected children and adolescents

by ethlyn

Linda Barlow-Mosha*. 1. , Grace Miriam . Ahimbisib...

Paediatric ARV Drug Optimization 3 Review Summary report &

Paediatric ARV Drug Optimization 3 Review Summary report &

by neoiate

*\n\b...

Heather Watts MD Director of HIV Prevention, Program Quality Team

Heather Watts MD Director of HIV Prevention, Program Quality Team

by alida-meadow

Heather Watts MD Director of HIV Prevention, Pro...

Dolutegravir monotherapy

Dolutegravir monotherapy

by alexa-scheidler

Dolutegravir monotherapy vs. dolutegravir/ abac...

Projecting the Impact of

Projecting the Impact of

by marina-yarberry

Generic. HIV . Drugs. on 90-90-90. Esteban Burr...

SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN

SWITCHING TO DTG/3TC FIXED-DOSE COMBINATION (FDC) IS NON-INFERIOR TO CONTINUING A TAF-BASED REGIMEN

by jacey

1. ViiV Healthcare, Brentford, UK; . 2. Centre Hos...

DTG vs LPV/r (DAWNING): Efficacy

DTG vs LPV/r (DAWNING): Efficacy

by winnie

by Baseline NRTI Resistance . and Second-Line NRTI...

DTG/3TC 1st line (GEMINI)

DTG/3TC 1st line (GEMINI)

by oryan

ARV . strategies. DOR > DRV/r 1st line. (DRIVE-...

Switch to DTG/3TC TANGO Design

Switch to DTG/3TC TANGO Design

by lam

Endpoints. Primary: proportion of patients with HI...

Switch to DTG/ABC/3TC

Switch to DTG/ABC/3TC

by karlyn-bohler

STRIIVING . Study. Design. Endpoints. Primary: pr...

DTG-Based Regimens Are Active in INI-Naive Patients With a

DTG-Based Regimens Are Active in INI-Naive Patients With a

by trish-goza

Jim Demarest. ,. 1. Mark Underwood,. 2. Marty S...

Update from CROI 2023: Snippets from Seattle

Update from CROI 2023: Snippets from Seattle

by scarlett

Judith S. Currier, MD, MSc. Professor of Medicine....

New Antiretrovirals for the Treatment

New Antiretrovirals for the Treatment

by alida-meadow

of HIV. . Convenience, tolerability, simplicity....

Working Group on Modelling Potential Responses to High Levels of pre-ART Drug Resistance in Sub-Sah

Working Group on Modelling Potential Responses to High Levels of pre-ART Drug Resistance in Sub-Sah

by debby-jeon

HIV Drug Resistance (HIVDR) and Antimicrobial Res...

2013 Asilomar HIV Medical Update

2013 Asilomar HIV Medical Update

by luanne-stotts

David Spach, MD. Clinical Director, Northwest AET...

Cases from the Clinic(ians): Case-based Panel Discussion

Cases from the Clinic(ians): Case-based Panel Discussion

by tripp

Associate Dean for Global Health. University of Al...

Interactive ART Cases From the Clinic: Is There One Right Answer?

Interactive ART Cases From the Clinic: Is There One Right Answer?

by megan

Joseph J. Eron, Jr, MD. Professor of Medicine. Uni...

JM Llibre , 1 C-C Hung,

JM Llibre , 1 C-C Hung,

by mohammad106

2. C Brinson,. 3. F Castelli,. 4. P-M Girard,. ...

Custom Hoodies - No Minimum, Custom DTG Atlanta at 3V Printing Store

Custom Hoodies - No Minimum, Custom DTG Atlanta at 3V Printing Store

by 3vprintingstore

In the bustling city of Atlanta, fashion-forward i...

Updates on Individual and Universal HIV Treatment Strategies

Updates on Individual and Universal HIV Treatment Strategies

by norah

EECA INTERACT, November 19, 2019. Stefan Baral, MD...

Antiretrovirals for prevention in women of childbearing age:

Antiretrovirals for prevention in women of childbearing age:

by tremblay

issues to consider. Landon Myer. We all have “is...

Optimization of Antiretroviral Therapy

Optimization of Antiretroviral Therapy

by belinda

With Emergence of Comorbidities. Roger J. . Bedimo...

Basic HIV Course for Health Professionals

Basic HIV Course for Health Professionals

by megan

Session 12: Contraceptives and HIV. Learning Objec...

Emergence of resistance in

Emergence of resistance in

by emma

HIV-1 Integrase . following dolutegravir (DTG) tre...

The Fast and The Continuous:

The Fast and The Continuous:

by bery

Dolutegravir-based Antiretroviral Therapy Achieves...

Thinking of Now and Tomorrow: Emerging Treatment Paradigms

Thinking of Now and Tomorrow: Emerging Treatment Paradigms

by deena

Pedro Cahn. Disclosures. Advisory. . boards. : Me...

Challenging Cases in Antiretroviral Therapy and Panel Discussion

Challenging Cases in Antiretroviral Therapy and Panel Discussion

by gagnon

Paul E. Sax, MD. Professor of Medicine. Harvard Me...

What’s new in the 2019 WHO Guidelines:

What’s new in the 2019 WHO Guidelines:

by elina

Dolutegravir based regimens in first- ad second-li...